REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting

Phase 2

Phase 3

Luveltamab Tazevibulin vs. IC ChemotherapyREFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Sponsor:

Sutro Biopharma, Inc.

Code:

NCT05870748

Conditions

Ovarian Cancer

Epithelial Ovarian Cancer

Fallopian Tube Cancer

Primary Peritoneal Cancer

Platinum-resistant Ovarian Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Luveltamab tazevibulin

Pegfilgrastim

Gemcitabine

Paclitaxel

Pegylated liposomal doxorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Sutro Biopharma, Inc. on 2024-08-29.